Continued Pressure for Alveolar Protection (CPAP Trial)
ConditionBronchopulmonary Dysplasia (BPD)
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeUp to 31
SponsorNICHD Neonatal Research Network
About this trial
The objective of the CPAP Trial is to test whether extending CPAP until 34 weeks' PMA or for at least 2 additional weeks compared to weaning to a nasal canula will decrease the likelihood of bronchopulmonary dysplasia or death at 36 weeks' PMA.
Eligibility criteria
Qualifiers
Gestational age <29 weeks at birth
PMA <32 weeks at study entry
On treatment with CPAP without a rate in FiO2 <0.25 and PEEP of 4-5 cmH2O
If previously intubated must be extubated ≥ 72 hours
Disqualifiers
Major malformation
Neuromuscular condition that affects respiration
Terminal illness
Decision to withhold or limit support
Trial design
Treatments tested in this trial
- CPAP
- Nasal Cannula
Treatment groups
860 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
NICHD Neonatal Research Network
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
Source ClinicalTrials.gov